Biopharmaceutical company Faron Pharmaceuticals Ltd (AIM: FARN) (First North: FARON) on Monday reported new Phase I/II BEXMAB trial data showing enhanced efficacy for its lead asset, bexmarilimab, in treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS) patients. The results were presented by Dr Mika Kontro of Helsinki University Hospital at the European Society for Medical Oncology (ESMO) Congress 2025.
In combination with azacitidine, bexmarilimab achieved an 85% objective response rate (ORR) and a 45% complete remission rate in 20 evaluable treatment-naïve HR-MDS patients. More than half of patients (55%) achieved full clearance of bone marrow blasts, with deeper engagement of the Clever-1 target correlating strongly with improved outcomes. Patients with low baseline blast counts (
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA